Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: Dissecting the function and pharmacology of PDK1

Journal of Medicinal Chemistry

Volumn 56, Issue 7, 2013, Pages 2726-2737

  Medina, Jesús R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; ALKYL GROUP; BX 320; BX 795; CHECKPOINT KINASE 2; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; GSK 2334470; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN; OSU 03013; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN S6; PROTEIN SERINE THREONINE KINASE INHIBITOR; S6 KINASE; SOMATOMEDIN C; TAMOXIFEN; UNCLASSIFIED DRUG;

CANCER CELL; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN HEK293; CELL SURVIVAL; EMBRYONIC STEM CELL; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; ISOTHERMAL TITRATION CALORIMETRY; LIPOPHILICITY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PH; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RNA INTERFERENCE; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84876273770     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4000227     Document Type: Review

References (62)

1. Bunnage, M. E. Getting pharmaceutical R&D back on target Nat. Chem. Biol. 2011, 7, 335-339
2. Gashaw, I.; Ellinghaus, P.; Sommer, A.; Asadullah, K. What makes a good drug target? Drug Discovery Today 2011, 16, 1037-1043
3. Hoelder, S.; Clarke, P. A.; Workman, P. Discovery of small molecule drugs: successes, challenges and opportunities Mol. Oncol. 2012, 6, 155-176
4. Quon, K.; Kassner, P. D. RNA interference screening for the discovery of oncology targets Expert Opin. Ther. Targets 2009, 13, 1027-1035
5. Cohen, P. Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation Biochem. J. 2010, 425, 53-54
6. Workman, P.; Collins, I. Probing the probes: fitness factors for small molecule tools Chem. Biol. 2010, 17, 561-577
7. Knight, Z. A.; Shokat, K. M. Chemical genetics, where genetics and pharmacology meet Cell 2007, 128, 425-430
8. Miyazawa, K. Encountering unpredicted off-target effects of pharmacological inhibitors J. Biochem. 2011, 150, 1-3
9. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39
10. Bain, J.; Plater, L.; Elliot, M.; Shpiro, N.; Hastie, C. J.; McLauchlan, H.; Klevernic, I.; Arthur, J. S. C.; Alessi, D. R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update Biochem. J. 2007, 408, 297-315
11. Liao, J. J-L. Molecular recognition of protein binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 2007, 50, 409-424
12. Barile, E.; De, S. K.; Pellecchia, M. PDK1 inhibitors Pharm. Pat. Analyst 2012, 1, 145-163
13. Raimondi, C.; Falasca, M. Targeting PDK1 in Cancer Curr. Med. Chem. 2011, 18, 2763-2769
14. Peifer, C.; Alessi, D. R. Small-molecule inhibitors of PDK1 ChemMedChem 2008, 3, 1810-1838
15. Pearce, L. R.; Komander, D.; Alessi, D. R. The nuts and bolts of AGC protein kinases Nat. Rev. Mol. Cell Biol. 2010, 9-22
16. Alessi, D. R.; James, S. R.; Downes, C. P.; Holmes, A. B.; Gaffney, P. R.; Reese, C. B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha Curr. Biol. 1997, 7, 261-269
17. Stokoe, D.; Stephens, L. R.; Copeland, T.; Gaffney, P. R. J.; Reese, C. B.; Painter, G. F.; Holmes, A. B.; McCormic, F.; Hawkins, P. T. Dual role of phosphatidylinositol-3,4,5-triphosphate in the activation of protein kinase B Science 1997, 277, 567-570
18. Milburn, C. C.; Deak, M.; Kelly, S. M.; Price, N. C.; Alessi, D. R.; Van Aalten, D. M. Binding of phosphatidylinositol 3,4,5-triphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change Biochem. J. 2003, 375, 531-638
19. Biondi, R. M.; Kieloch, A.; Currie, R. A.; Deak, M.; Alessi, D. R. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGC, but not PKB EMBO J. 2001, 20, 4380-4390
20. Mora, A.; Komander, D.; Van Aalten, D. M. F.; Alessi, D. R. PDK1, the master regulator of AGC kinase signal transduction Semin. Cell Dev. Biol. 2004, 15, 161-170
21. Bayascas, J. R.; Leslie, N. R.; Parsons, R.; Fleming, S.; Alessi, D. R. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice Curr. Biol. 2005, 15, 1839-1846
22. Zhu, J.; Huang, J. W.; Tseng, P. H.; Yang, Y. T.; Fowble, J.; Shiau, C. W.; Shaw, Y. J.; Kulp, S. K.; Chen, C. S. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinisitide-dependent protein kinase-1 inhibitors Cancer Res. 2004, 64, 4309-4318
23. Feldman, R. I.; Wu, J. M.; Polokoff, M. A.; Kochanny, M. J.; Dinter, H.; Zhu, D.; Biroc, S. L.; Alicke, B.; Bryant, J.; Yuan, S.; Buckman, B. O.; Lentz, D.; Ferrer, M.; Whitlow, M.; Adler, M.; Finster, S.; Chang, Z.; Arnaiz, D. O. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 J. Biol. Chem. 2005, 280, 19867-19874
24. Tamgüney, T.; Zhang, C.; Fiedler, D.; Shokat, K.; Stokoe, D. Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells Exp. Cell Res. 2008, 314, 2299-2312
25. Poulsen, A.; Blanchard, S.; Soh, C. K.; Lee, C.; Williams, M.; Wang, H.; Dymock, B. Structure-based design of PDK1 inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 305-307
26. Yang, W.; AbdulHameed, M. D. M.; Hamza, A.; Zhan, C. G. New inhibitor of 3-phosphoinositide dependent protein kinase-1 identified from virtual screening Bioorg. Med. Chem. Lett. 2012, 22, 1629-1632
27. Johnson, M. C.; Hu, Q.; Lingardo, L.; Ferre, R. A.; Greasley, S.; Yan, J.; Kath, J.; Chen, P.; Ermolieff, J.; Alton, G. Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery J. Comput.-Aided Mol. Des. 2011, 25, 689-698
28. Angiolini, M.; Banfi, P.; Casale, E.; Casuscelli, F.; Fiorelli, C.; Saccardo, M. B.; Silvagni, M.; Zuccotto, F. Structure-based optimization of potent PDK1 inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 4095-4099
29. Medina, J. R.; Becker, C. J.; Blackledge, C. W.; Duquenne, C.; Feng, Y.; Grant, S. W.; Heerding, D.; Li, W. H.; Miller, W. H.; Romeril, S. P.; Scherzer, D.; Shu, A.; Bobko, M. A.; Chadderton, A. R.; Dumble, M.; Gardiner, C. M.; Gilbert, S.; Liu, Q.; Rabindran, S. K.; Sudakin, V.; Xiang, H.; Brady, P. G.; Campobasso, N.; Ward, P.; Axten, J. M. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors J. Med. Chem. 2011, 54, 1871-1895
30. Murphy, S. T.; Alton, G.; Bailey, S.; Baxi, S. M.; Burke, B. J.; Chappie, T. A.; Ermolieff, J.; Ferre, R.; Greasley, S.; Hickey, M.; Humphrey, J.; Kablaoui, N.; Kath, J.; Kazmirski, S.; Kraus, M.; Kupchinski, S.; Li, J.; Lingardo, L.; Marx, M. A.; Richter, D.; Tanis, S. P.; Tran, K.; Vernier, W.; Xie, Z.; Yin, M. J.; Yu, X. H. Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1) J. Med. Chem. 2011, 54, 8490-8500
31. Erlanson, D. A.; Arndt, J. W.; Cancilla, M. T.; Cao, K.; Elling, R. A.; English, N.; Friedman, J.; Hansen, S. K.; Hession, C.; Joseph, I.; Kumaravel, G.; Lee, W. C.; Lind, K. E.; McDowell, R. S.; Miatkowski, K.; Nguyen, C.; Nguyen, T. B.; Park, S.; Pathan, N.; Penny, D. M.; Romanowski, M. J.; Scott, D.; Silvian, L.; Simmons, R. L.; Tangonan, B. T.; Yang, W.; Sun, L. Discovery of a potent and highly selective inhibitor via fragment-based drug discovery Bioorg. Med. Chem. Lett. 2011, 21, 3078-3083
32. Falasca, M.; Chiozzotto, D.; Godage, H. Y.; Mazzoletti, M.; Riley, A. M.; Previdi, S.; Potter, B. V. L; Broggini, M.; Maffuci, T. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6- pentakisphosphate Br. J. Cancer 2010, 102, 104-114
33. Medina, J. R.; Blackledge, C. W.; Heerding, D. A.; Campobasso, N.; Ward, P.; Briand, J.; Wright, L.; Axten, J. M. Aminoindazole PDK1 inhibitors: a case study in fragment-based drug discovery ACS Med. Chem. Lett. 2010, 1, 439-442
34. Najafov, A.; Sommer, E. M.; Axten, J. M.; DeYoung, M. P.; Alessi, D. R. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1 Biochem. J. 2011, 433, 357-369
35. Alessi, D. R.; Deak, M.; Casamayor, A.; Caudwell, F. B.; Morrice, N.; Norman, D. G.; Gaffney, P.; Reese, C. B.; MacDougall, C. N.; Harbison, D.; Ashworth, A.; Bownes, M. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase Curr. Biol. 1997, 7, 776-789
36. Alessi, D. R.; Kozlowski, M. T.; Weng, Q. P.; Morrice, N.; Avruch, J. 3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro Curr. Biol. 1998, 8, 69-81
37. 3-dependent mechanism leading to resistance to PDK1 inhibitors Biochem. J. 2012, 448, 285-295
38. Ellwood-Yen, K.; Keilhack, H.; Kunii, K.; Dolinski, B.; Connor, Y.; Hu, K.; Nagashima, K.; O'Hare, E.; Erkul, Y.; Bacco, A. D.; Gargano, D.; Shomer, N. H.; Angagaw, M.; Leccese, E.; Andrade, P.; Hurd, M.; Shin, M. K.; Vogt, T. F.; Nothrup, A.; Bobkova, E. V.; Kasibhatla, S.; Bronson, R. T.; Scott, M. L.; Draetta, G.; Richon, V.; Kohl, N.; Blume-Jensen, P.; Andersen, J. N.; Kraus, M. PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models Cancer Res. 2011, 71, 3052-3065
39. Axten, J. M.; Medina, J. R.; Shu, A.; Li, W.; Feng, Y.; DeYoung, M. P.; Gardiner, C. M.; Chadderton, A. R.; Dumble, M.; Liu, Q.; Rabindran, S. K. GSK2334470: A Potent and Highly Selective Inhibitor of PDK1. Abstracts of Papers, 101st Annual Meeting of AACR, Washington DC, April 17-21, 2010; AACR: Philadelphia, PA, 2010; Abstract LB-116.
40. Erlanson, D. A.; Lam, J. W.; Wiesmann, C.; Luong, T. N.; Simmons, R. L.; DeLano, W. L.; Choong, I. C.; Burdett, M. T.; Flanagan, W. M.; Lee, D.; Gordon, E. M.; O'Brien, T. In situ assembly of enzyme inhibitors using extended tethering Nat. Biotechnol. 2003, 21, 308-314
41. Nagashima, K.; Shumway, S. D.; Sathyanarayanan, S.; Chen, A. H.; Dolinski, B.; Xu, Y.; Keilhack, H.; Nguyen, T.; Wiznerowicz, M.; Li, L.; Lutterbach, B. A.; Chi, A.; Paweletz, C.; Allison, T.; Yan, Y.; Munshi, S. K.; Klippel, A.; Kraus, M.; Bobkova, E. V.; Deshmukh, S.; Xu, Z.; Mueller, U.; Szewczak, A. A.; Pan, B. S.; Richon, V.; Pollock, R.; Blume-Jensen, P.; Northrup, A.; Andersen, J. N. Genetic and pharmacological inhibition of PDK1 in cancer cells. Characterization of a selective allosteric kinase inhibitor J. Biol. Chem. 2011, 286, 6433-6448
42. Bayascas, J. R.; Wullschleger, S.; Sakamoto, K.; García- Martínez, J. M.; Clacher, C.; Komander, D.; van Aalten, D. M.; Boini, K. M.; Lang, F.; Lipina, C.; Logie, L.; Sutherland, C.; Chudek, J. A.; van Diepen, J. A.; Voshol, P. J.; Lucocq, J. M.; Alessi, D. R. Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance Mol. Cell. Biol. 2008, 28, 3258-3272
43. McManus, E. J.; Collins, B. J.; Ashby, P. R.; Prescott, A. R.; Murray-Tait, V.; Armit, L. J.; Arthur, J. S.; Alessi, D. R. The in vivo role of PtIns(3,4,5)P3 binding to PDK1 PH domain by knockin mutation EMBO J. 2004, 23, 2071-2082
44. Carracedo, A.; Pandolfi, P. P. The PTEN-PI3K pathway: of feedbacks and cross-talks Oncogene 2008, 27, 5527-5541
45. Piccolo, E.; Vignati, S.; Maffuci, T.; Innominato, P. F.; Riley, A. M.; Potter, B. V.; Pandolfi, P. P.; Broggini, M.; Iacobelli, S.; Innocenti, P.; Falasca, M. Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway Oncogene 2004, 23, 1754-1765
46. Razzini, G.; Berrie, C. P.; Vignati, S.; Broggini, M.; Mascetta, G.; Brancaccio, A.; Falasca, M. Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines FASEB J. 2000, 14, 1179-1187
47. Maffucci, T.; Falasca, M. Specificity in pleckstrin homology (PH) domain membrane targeting: a role for a phosphoinositide-protein co-operative mechanism FEBS Lett. 2001, 506, 173-179
48. Iorns, E.; Lord, C. J.; Ashworth, A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization Biochem. J. 2009, 417, 361-370
49. Engel, M.; Hindie, V.; Lopez-Garcia, L. A.; Stroba, A.; Schaeffer, F.; Adrian, I.; Imig, J.; Idrissova, L.; Nastainczyk, W.; Zeuzem, S.; Alzari, P. M.; Hartmann, R. W.; Piiper, A.; Biondi, R, M. Allosteric activation of the protein kinase PDK1 with low molecular weight compounds EMBO J. 2006, 25, 5469-5480
50. 15N TROSY experiments Chem. Biol. Drug Des. 2009, 73, 179-188
51. Bobkova, E. V.; Weber, M. J.; Xu, Z.; Zhang, Y. L.; Jung, J.; Blume-Jensen, P.; Northrup, A.; Kunapuli, P.; Andersen, J. N.; Kariv, I. Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening J. Biol. Chem. 2010, 285, 18838-18846
52. Wei, L.; Gao, X.; Warne, R.; Hao, X.; Bussiere, D.; Gu, X.; Uno, T.; Liu, Y. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1 Bioorg. Med. Chem. Lett. 2010, 20, 3897-3902
53. Hindie, V.; Stroba, A.; Zhang, H.; Lopez-Garcia, L. A.; Idrissova, L.; Zeuzem, S.; Hirschberg, D.; Schaeffer, F.; Jørgensen, T. J. D.; Engel, M.; Alzari, P. M.; Biondi, R. M. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1 Nat. Chem. Biol. 2009, 5, 758-764
54. Stroba, A.; Schaeffer, F.; Hindie, V.; Lopez-Garcia, L.; Adrian, I.; Fröhner, W.; Hartman, R. W.; Biondi, R. M.; Engel, M. 3,5-Diphenylpent-2- enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds J. Med. Chem. 2009, 52, 4683-4693
55. Busschots, K.; Lopez-Garcia, L. A.; Lammi, C.; Stroba, A.; Zeuzem, S.; Piiper, A.; Alzari, P. M.; Neimanis, S.; Arencibia, J. M.; Engel, M.; Schulze, J. O.; Biondi, R. M. Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site Chem. Biol. 2012, 19, 1152-1163
56. Wilhelm, A.; Lopez-Garcia, L. A.; Busschots, K.; Fröhner, W.; Maurer, F.; Boettcher, S.; Zhang, H.; Schulze, J. O.; Biondi, R. M.; Engel, M. 2-(3-Oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1: development and prodrug concept J. Med. Chem. 2012, 55, 9817-9830
57. Biondi, R. M.; Cheung, P. C.; Casamayor, A.; Deak, M.; Currie, R. A.; Alessi, D. R. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA EMBO J. 2000, 19, 979-988
58. Liao, J. J.-L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors J. Med. Chem. 2007, 50, 409-424
59. Falasca, M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs Curr. Pharm. Des. 2010, 16, 1410-1416
60. Mavrommati, I.; Maffucci, T. mTOR inhibitors: facing new challenges ahead Curr. Med. Chem. 2011, 18, 2743-2762
61. Willems, L.; Tamburini, J.; Chapuis, N.; Lacombe, C.; Mayeux, P.; Bouscary, D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies Curr. Oncol. Rep. 2012, 14, 129-138
62. Chresta, C. M.; Davies, B. R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S. E.; Vincent, J. P.; Ellston, R.; Jones, D.; Sini, P.; James, D.; Howard, Z.; Dudley, P.; Hughes, G.; Smith, L.; Maguire, S.; Hummerson, M.; Malagu, K.; Menear, K.; Jenkins, R.; Jacobsen, M.; Smith, G. C.; Guichard, S.; Pass, M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity Cancer Res. 2010, 70, 288-298